Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Vividrin 2% eye drops
1104020T0BFAAAA
|
Vividrin (Eye) | Sodium cromoglicate | Eye | No data available |
|
Vividrin 2% eye drops 0.5ml unit dose preservative free
1104020T0BFABAG
|
Vividrin (Eye) | Sodium cromoglicate | Eye | No data available |
|
Vividrin 2% nasal spray (Bausch & Lomb)
1202010P0BEAAAH
|
Vividrin (Nasal) | Sodium cromoglicate | Ear, Nose and Oropharynx | No data available |
|
Vividrin 2% nasal spray (Imported)
1202010P0BEABAH
|
Vividrin (Nasal) | Sodium cromoglicate | Ear, Nose and Oropharynx | No data available |
|
Vivioptal Active capsules
091200000BFWLFS
|
Proprietary compound preparation BNF 0912000 | Other health supplement preparations | Nutrition and Blood | No data available |
|
Vivioptal capsules
091000000BBVEA0
|
Proprietary compound preparation BNF 0910000 | Other compound vitamin/mineral formulation preparations | Nutrition and Blood | No data available |
|
Vivioptal Plus capsules
091200000BFWMFS
|
Proprietary compound preparation BNF 0912000 | Other health supplement preparations | Nutrition and Blood | No data available |
|
Vivomixx drops
091104000BBPMBH
|
Proprietary compound preparation BNF 0911040 | Other digestive aid preparations | Nutrition and Blood | No data available |
|
Vivomixx neo oral powder 4.4g sachets
0913531C0BBABAF
|
Vivomixx powder delisted probiotic | Powder delisted probiotic (0913531) | Nutrition and Blood | No data available |
|
Viz-On 2% eye drops
1104020T0BJAAAA
|
Viz-On | Sodium cromoglicate | Eye | No data available |
|
Vizarsin 100mg tablets
0704050Z0BEADAC
|
Vizarsin | Sildenafil (Erectile Dysfunction) | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
|
Vizarsin 25mg tablets
0704050Z0BEAAAB
|
Vizarsin | Sildenafil (Erectile Dysfunction) | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
|
Vizarsin 50mg tablets
0704050Z0BEABAA
|
Vizarsin | Sildenafil (Erectile Dysfunction) | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
|
Vizibim 0.3mg/ml eye drops
1106000AFBFAAAD
|
Vizibim | Bimatoprost | Eye | No data available |
|
Vizimpro 15mg tablets
0801050CQBBAAAA
|
Vizimpro | Dacomitinib | Malignant Disease and Immunosuppression | No data available |
|
Vizimpro 30mg tablets
0801050CQBBABAB
|
Vizimpro | Dacomitinib | Malignant Disease and Immunosuppression | No data available |
|
Vizimpro 45mg tablets
0801050CQBBACAC
|
Vizimpro | Dacomitinib | Malignant Disease and Immunosuppression | No data available |
|
Vizulize 0.1% eye drops
21300000186
|
Vizulize 0.1% eye drops | Eye Products | Appliances | No data available |
|
Vizulize Hypromellose 0.3% eye drops
21300000184
|
Vizulize Hypromellose 0.3% eye drops | Eye Products | Appliances | No data available |
|
Vizulize Intensive 0.3% eye drops
21300000187
|
Vizulize Intensive 0.3% eye drops | Eye Products | Appliances | No data available |
|
Vocabria 30mg tablets
0503010AWBBAAAA
|
Vocabria | Cabotegravir | Infections | No data available |
|
Vocabria 600mg/3ml prolonged-release inj vials
0503010AWBBABAB
|
Vocabria | Cabotegravir | Infections | No data available |
|
Vocalzone Throat pastilles blackcurrant
1203030N0BIACA0
|
Vocalzone | Menthol | Ear, Nose and Oropharynx | No data available |
|
Vocalzone Throat pastilles honey & lemon
1203030N0BIADA0
|
Vocalzone | Menthol | Ear, Nose and Oropharynx | No data available |
|
Voiceline II speaking valve (blue)
20050600173
|
Voiceline II speaking valve (blue) | Tracheostomy & Laryngectomy Appliances | Dressings | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.